Use of the MyDose Coach Digital Tool for Self-titration of Insulin in Patients With Type 2 Diabetes
NCT ID: NCT03775057
Last Updated: 2018-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2018-08-22
2019-08-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary Objective:
To evaluate the efficacy and safety of the MyDose Coach digital tool in patients with T2D with basal insulin or candidates for the use of basal insulin.
Secondary Objectives:
Evaluate demographic variables and control variables (HbA1c, SMPG, FPG). Measure the units of insulin used before and after the intervention
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MyDose Coach app intervention
The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
MyDoseCoach app
The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MyDoseCoach app
The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Greater than 18 years and up to 75 years of age
* Use of basal insulin once a day or candidate for basal insulin once a day based on% HbA1c according to international guidelines and doctor's criteria
* HbA1c \> 7% in patients aged 18 to 65 years
* HbA1c \> 7.5% in patients older than 65 years
* Patients who use basal insulin twice a day or premix with diagnosed hypoglycemia and who are candidates for switching from therapy to a basal insulin of one application per day
* Have a Smartphone
* Informed consent signature
Exclusion Criteria
* Age younger than 18 years old and over 75 years old.
* Diabetes type 1 or gestational (other than type 2 diabetes mellitus).
* Patients with the following chronic complications of diabetes: retinopathy and chronic kidney disease with a glomerular filtration rate \<30 ml / min.
* The MyDose Coach tool is not appropriate for the patient or the use of the application is contraindicated (in the opinion of the Researcher, for example, patients with terminal illness, patients with cognitive or neurological disorders that are detailed below, patients who live alone and they do not have support from the family, patients with carpal tunnel who are not recommended to use a mobile phone, patients with musculoskeletal injuries in their hands, etc.)
* Patients who use insulin during the meal (short-acting analogue, regular human insulin or insulin premix) for more than 10 days in the last 3 months before the screening visit.
* Patients with severe hypoglycemia in the last 90 days.
* Hospitalization in the last 30 days (whatever the reason for hospitalization) In the last 3 months prior to the screening period: history of myocardial infarction, unstable angina, acute coronary syndrome, revascularization procedure, cerebrovascular accident requiring hospitalization.
* Severe or uncontrolled congestive heart failure (functional classification III and IV of the New York Heart Association \[NYHA\]).
* Use of systemic glucocorticoids (excluding topical application or inhaled forms) for a week or more within 90 days prior to the time of the test.
* Unable to meet specific protocol requirements (for example, inability to perform blood glucose measurements, administer your own insulin dose, or consider it unlikely that you will administer the titration safely according to your physician's guidance).
* Patients with cognitive disorders, dementia or any neurological disorder that affects the patient's ability to participate in the study, including the inability to understand the requirements of the study or to provide complete information about the adverse symptoms.
* Pregnant or breast-feeding women or women who intend to become pregnant during the study period.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Clinica Nova
OTHER
Hospital Universitario Dr. Jose E. Gonzalez
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. med. Hector Eloy Tamez Perez
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clínica Nova
San Nicolás de los Garza, Nuevo León, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hector Eloy Tamez, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIE01-18
Identifier Type: -
Identifier Source: org_study_id